# A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

> **NCT04420130** · NA · WITHDRAWN · sponsor: **Yanqiao Zhang**

## Conditions studied

- Pancreatic Cancer
- Liver Metastasis

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Chemotherapy
- **PROCEDURE:** Ablation

## Key facts

- **NCT ID:** NCT04420130
- **Lead sponsor:** Yanqiao Zhang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Failed to pass ethics committee review
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04420130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04420130, "A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04420130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*